Nirsevimab linked to marked reduction in paediatric RSV hospitalisations, real-world study shows
From the article
Introduction of the monoclonal antibody nirsevimab in routine clinical practice is associated with a 51% reduction in respiratory syncytial virus (RSV)-related hospitalisations among children under two years of age, according to a real-world study conducted at a large German tertiary centre. RSV is one of the leading causes of hospitalisation in infants and young children, […] The post Nirsevimab linked to marked reduction in paediatric RSV hospitalisations, real-world study shows appeared first on Hospital Healthcare Europe .
Continue reading on hospitalhealthcare.comYou might also wanna read
Generalisability of proposed clinical sepsis phenotypes questioned by international validation study
hospitalhealthcare.com·1d ago
Evidence linking legume and soy intake with reduced hypertension risk strengthens
hospitalhealthcare.com·2d ago
Delgocitinib cream linked to low systemic exposure in chronic hand eczema, post hoc analysis shows
hospitalhealthcare.com·5d ago
Shaping the future of cardio-oncology: insights from ESC Cardio-Oncology 2026 and beyond
hospitalhealthcare.com·5d ago
Respiratory oscillometry shows considerable potential for infant lung assessment
hospitalhealthcare.com·6d ago
Bidirectional phenotype switching between psoriasis and atopic dermatitis characterised
hospitalhealthcare.com·6d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.